The glycosylation pattern of a chimeric heavy chain antibody (EG2) produced from CHO cells was affected by the glucose concentration (0-25 mM) of cultures established at high density (>10 6 ml -1 ) over 24 h. The resulting proportion of non-glycosylated Mab was directly correlated to the exposure time of cells to media depleted of glucose. Deprivation of glucose for the full 24 h resulted in a 45% non-glycosylated Mab fraction.
Introduction
The increasing demand for recombinant therapeutic proteins, especially recombinant monoclonal antibodies (Mabs), has been met by significant increases in productivity of mammalian cell culture bioprocess over the last decade (Butler, 2005; Wurm, 2004) . Fed-batch culture has become the predominant strategy used for mammalian cell culture bioprocesses for biopharmaceutical production (Rouiller et al., 2013; Xie et al., 1997) . The value of this strategy is to prolong the stationary phase of the culture in which viable cells are held at a high density in a productive state for several days.
Optimally designed feeding regimes with low concentrations of glucose and glutamine have been shown to lead to an efficient energy metabolism with minimal production of lactate and ammonia and a substantial increase of the productivity of a targeted protein (Dean and Reddy, 2013; Kim do et al., 2013 ). However, the precise feeding regime can lead to intermittent periods in which the substrates (notably glucose) may be reduced to levels that are critical to glycosylation (Xie et al., 1997) .
N-glycosylation is the predominant type of post-translational modification that can affect the efficacy of a biopharmaceutical. Marked effects of the glycosylation profile of the glycoprotein include the enhancement of effector function (Jefferis, 2012) , pharmacokinetics (Bumbaca et al., 2012) , pharmacodistribution (Werner et al., 2007) , antigenicity (Zhu et al., 2002) , stability (Zheng et al., 2011) and solubility (Lee and Forciniti, 2013) . Given the variety of potential effects of N-glycosylation on bioactivity of a glycoprotein, an understanding of the glycosylation machinery and the metabolic parameters that affect the heterogeneity of Nglycosylation during Mabs production is important to ensure the production of both a consistent glycosylation profile and one with a pre-determined clinical outcome.
N-glycosylation variations in mammalian cell bioprocesses may be found in the site-occupancy (macroheterogeneity) or glycan profile (microheterogeneity) as a result of various cell culture factors including nutrient limitation (Andersen et al., 2000; Curling et al., 1990) . Structural variants of attached glycan structures produced from any cell are governed by a network of complementary and competing enzymes that do not always allow individual reactions to go to completion. This network is affected by multiple factors including the availability of precursor, co-factors and enzyme activities levels (Butler, 2006) all of which give rise to variable final glycan structure (microheterogeneity). The functional importance of the glycan profile has been recognized. Changes in glycan microheterogeneity in monoclonal antibodies, Mabs, have been recorded in vivo under physiological or pathological conditions. The enhancement of complement activation has been correlated with an increase in galactosylation of antibodies (Tsuchiya et al., 1989) and an enhanced anti-inflammatory effect with increased sialylation of antibodies (Kaneko et al., 2006; Scallon et al., 2007) .
During Mab production from mammalian cell culture numerous parameters may have an impact on the heterogeneity of glycan structures. These include the availability of medium components, and culture environmental parameters. It has been known for some time that lower levels of glucose can lead to decreased site occupancy (Stark and Heath, 1979) or aberrant structure (Rearick et al., 1981) . In one report of a fed-batch culture glucose <4 mM was shown to lead to extended periods of high cell viability through minimal by-product formation but further reduction (glc < 0.7 mM) resulted in decreased sialylation and the appearance of aberrant glycan structures of secreted gamma-interferon (Chee Furng Wong et al., 2005) . Furthermore, microheterogeneity of glycans may be affected by various culture parameters (Butler, 2006) including the mode of culture (Andersen and Goochee, 1994) , culture pH (Borys et al., 1993) , specific media supplements (Crowell et al., 2008) or by-product accumulation . Typically, these variables affect the biosynthetic machinery within cells causing changes in the activity of glycosylating enzymes or the availability of critical metabolic precursors (Chen and Harcum, 2007) .
Glucose and glutamine are precursors for cellular energy metabolism as well as for the synthesis of intracellular nucleotidesugars that are essential substrates in N-glycosylation pathway. Glucose starvation has been shown to alter the biosynthesis of lipidlinked oligosaccharide (LLO) resulting in truncated precursors that may be transferred to proteins (Rearick et al., 1981a) . This can lead to reduced site occupancy even in feeding regimes where there may be a temporary depletion in substrate concentrations (Hayter et al., 1992; Xie et al., 1997) . The addition of specific substrates or co-factors has been shown to be a possible strategy to maximize terminal galactosylation (Grainger and James, 2013; Gramer et al., 2011) or sialylation (Gu and Wang, 1998) .
In this report we investigated the effect of varying periods of glucose starvation on the profile of intracellular LLO and the final glycan profile of a chimeric Mab produced from Chinese hamster ovary (CHO) cells.
Materials and methods

Cell line
A stably transfected CHO (DUXB) cell line (CHO-EG2 expressing a chimeric human-llama heavy chain monoclonal antibody (cHCAb) against epidermal growth factor receptor (EGFR) was gratefully received from Yves Durocher, NRC, Montreal (Zhang et al., 2009 ). The antibody (designated EG2) is a fusion of a camelid single domain antibody to a humanized Fc fragment and has a molecular weight ∼80 kDa. A second CHO cell line (DP12; clone #1934) was obtained from the American type culture collection (ATCC) for comparison of glycan profiles. This produces a human IgG Mab against interleukin 8.
Cell culture
The cells were maintained in cultures (80 mL) in 250 mL shake flasks in Biogro CHO media (Biogro Technologies Inc, Winnipeg, Canada) with 0.5 g/L yeast extract (BD, Sparks, USA) containing 25 mM glucose. The shake flasks were held in a humidified incubator at 120 rpm, 10% CO 2 and 37 • C.
A series of cultures were established at high density and variable glucose to determine differences in antibody glycosylation over 24 h. A pool of cells (2 × 10 8 ) was harvested following 3 days growth in standard culture media containing 25 mM glucose. These cells were inoculated at 2.6 × 10 6 cells/ml into 7 shake flasks (250 ml) each containing 80 ml of media with a different initial glucose concentration varying from 0 to 25 mM. A total of three trials were performed, with duplicate flasks at each glucose concentration. The high cell density at inoculation in these cultures was intended to ensure a rapid depletion of glucose from the media. The cultures were maintained and monitored under standard shaking conditions in an incubator over a 24 h period.
Cell culture sampling
Total cell counts and cell viability were measured at regular intervals by Trypan dye exclusion (0.5%) using a Cedex Image Analyzer (Innovates AG, Bielefeld, Germany). Glucose and lactate concentrations were determined enzymically using a YSI 2700 MBS Bioanalytical System (YSI Life Sciences, Yellow Springs, USA). The UMG supplements used to enhance galactosylation consisted of uridine (4 mM), manganese chloride (MnCl 2 , 8 M) and galactose (20 mM).
Antibody determination by ELISA
The EG2 antibody concentration was quantified by enzyme linked immunosorbent assay (ELISA). Goat produced anti-human IgG (Fc specific) antibodies (Sigma-Aldrich, St. Louis, USA, I21136) were used for coating ELISA plates (Invitrogen, Carlsbad, USA) in phosphate buffered saline (PBS) (Invitrogen, Carlsbad, USA) and blocked with PBS containing 3% (w/v) bovine serum albumin (BSA) (Sigma-Aldrich, St. Louis, USA) and 0.04% (w/v) Tween 20 (Sigma-Aldrich, St. Louis, USA, P1379). Supernatants of the culture samples were diluted with dilution buffer containing PBS, 0.5% (w/v) BSA and 0.04% Tween 20 and loaded onto the plates. An anti-human IgG (Fc specific) peroxidase-conjugated antibody produced in goat (Sigma-Aldrich, St. Louis, USA, A0170) was used for detection of EG2 antibody. The detection reagent consisted of 3,3 ,5,5 -tetramethylbenzidine dihydrochloride tablet (Sigma-Aldrich, St. Louis, USA, T3405) and 4 l of 30% hydrogen peroxide in 20 mL phosphate-citrate buffer (Sigma-Aldrich, St. Louis, USA, P4809). Sulphuric acid (2 M) was used as a stop solution. The titer was measured using an ELISA reader (Biotek, Winooski, USA) EL808 at 450 nm and Magellan software according to the instruction manual. The colorimetric measurements were converted to concentrations using a standard antibody solution (EG2) that was quantified by a Bradford assay and confirmed by a Lowry protein assay and ultraviolet absorption (A280).
Lipid-linked oligosaccharide (LLO) analysis
Cells were harvested and quenched to stop any subsequent metabolic activities (Sellick et al., 2009) . LLOs were extracted from the cells using a previously established method (Gao and Lehrman, Q2 2006). The chloroform/methanol/water fraction containing LLOs was subjected to mild acid hydrolysis and the released oligosaccharides were labeled with 2-aminobenzamide (2-AB; Sigma-Aldrich, St. Louis, USA) according to a previously developed method ( , 1995) and analyzed by high performance liquid chromatography (HPLC) (Waters, Milford, USA) using the technique of hydrophilic interaction liquid chromatography (HILIC). The HPLC instrument consisted of Waters 2475 binary pumps and a column heater, a Waters 717 autosampler, and a Waters 1425 fluorescent detector (set at excitation wavelength of 330 nm and an emission wavelength of 420 nm). The pumps and detector were controlled by Waters Empower software. The glycans were separated on a Waters X-Bridge 3.5 m amide column (4.6 × 250 mm) using 50 mM ammonium formate buffer (Buffer A) and acetonitrile (Buffer B). A linear gradient was run from 20% to 50% buffer A over 48 min (flow rate 0.86 mL/min) followed by a linear gradient to 100% A over 3 min (0.86 mL/min). The column temperature was controlled at 30 • C. The elution was calibrated to glucose units (GU) values using a 2-AB labeled glucose ladder (glucose homopolymer) and several standard 2-AB labeled N-linked glycans (Prozyme, Hayward, USA). The structures were assigned using standard GU values from the GlycoBase database (NIBRT.i.e.) (Campbell et al., 2008 ).
Microheterogeneity determination
Mabs were purified from culture supernatants with a Protein A affinity column (HP SpinTrap, GE Healthcare, Fairfield, USA) and run under denaturing conditions on 8-16% SDS-PAGE gels (Biorad, Hercules, USA) and stained with Coomassie Brilliant Blue (CBB). The protein bands were removed by scalpel, washed, and treated with Peptide-N-Glycosidase F (PNGase F; Roche Diagnostics, Indianapolis, USA) for 18 h to remove the attached glycans. The isolated N-linked glycans were labeled with 2-AB (Royle et al., 2006) . Glycan structures were assigned using standard GU values from HILIC analysis in GlycoBase. Structures were confirmed by exoglycosidase enzymatic digestion arrays using sialidase from recombinant A. ureafaciens; bovine kidney fucosidase; bovine testis ␤ (1-3,4)-galactosidase and jack bean ␤-N-acetylhexosaminidase (Prozyme, Hayward, USA) according to method of Royle et al. (2006) .
Macroheterogeneity determination
Antibodies were purified from culture supernatants with a Protein A affinity column. Some Mab preparations were then subjected to PNGase F digestion for 15, 30 or 60 min. The denatured proteins were loaded into 8-16% SDS-PAGE gels (Biorad, Hercules, USA) and stained with CBB.
Mass spectrometric analysis
MS analysis was carried out on the MALDI-TOF/TOF mass spectrometer (UltrafleXtreme TM , Bruker, Billerica, USA). Mass spectra obtained from intact antibody samples were recorded in the linear mode using sinapic acid as a matrix. Prior to glycan analysis, PNGase digested or hydrolyzed samples were purified on a Strata-X-C column (30 mg; Phenomenex, Torrance, USA). Evaporated fractions were re-constituted in 10 L of deionized water and spotted onto a partially dried matrix of 2,5-dihydroxybenzoic acid (DHB; Sigma, St. Louis, USA). The spectra were recorded in the reflectron mode. The instrument was calibrated externally using ACTH, angiotensin, bradykinin, bombesin, somastin and substance P over a mass range of 500-5000 Da. MS/MS experiments were performed using the LIFT cell; fragment ions were generated by laser-induced dissociation (LID) in the positive ion mode. Glycan structures were deduced from the fragmentation patterns obtained before and after exoglycosidase digestions.
Calculations
Cell specific glucose uptake (Q s ) was calculated from the growth data using the following equation:
where S, change in substrate concentration between time 0 and t, t 0 Nv.dt, integral of viable cell number between time 0 and t. The degree of galactosylation and sialylation of glycans was quantified by calculation of an index:
Where the galactosylation index (GI) is a value from 0 to 1 calculated from the proportional areas of peaks of non-galactosylated (G0), mono-galactosylated (G1) and di-galactosylated (G2) structures. The equation is based on the assumption that the G2 structure represents complete galactosylation of a biantennary glycan, whereas G1 represents 50% of full galactosylation and G0 represents zero galactosylation.
Similarly, the sialylation index (SI) was calculated from the proportional areas of all non-sialylated (S0), mono-sialylated (S1) and di-sialylated (S2) structures.
Results
Effect of glucose concentration on cell metabolites and protein productivity
A series of cultures were established at high density and variable glucose to determine differences in antibody glycosylation over 24 h as described in the Section 2. Cell concentrations increased under all glucose conditions (Fig. 1) . Yields of viable cells at >10 mM glucose was at least double the inoculation density and maintained a high viability (∼98%). At 5 mM glucose the viable cell concentration increased by 54% with a final viability ∼98%. At an initial 0 mM glucose the viable cell density increased by 21%, but the cell viability decreased to 90%. Fig. 2 shows the decrease in glucose concentration over the incubation period. Complete glucose depletion occurred at different time points in each culture with an initial glucose concentration below or at 15 mM. In these cultures cells were exposed to periods of glucose starvation for time periods between 2 and 24 h. For cultures with an initial glucose above or at 17.5 mM the substrate was not depleted during the incubation. The initial cell specific glucose consumption (Q glc ) was related to the glucose concentration and ranged from a maximum of 8.1 pmol/cell/day for the culture at 25 mM glucose to 4.5 pmol/cell/day for the culture at 5 mM glucose. These initial Q glc values decreased as the glucose was consumed over the 24 h incubation. The mean glucose consumption for each culture over this 24 h period is reported in Table 1 . Antibody production was measured at 6 h intervals during the 24 h incubation by ELISA. The antibody accumulated steadily under all conditions to a maximum of 10.1 g/ml after 24 h culture in 25 mM glucose compared to 4.3 g/ml in the absence of glucose (Table 1) . However, there was significant intrinsic variability in the ELISA assay as reflected in the results. The data showed a positive correlation between the initial glucose concentration in the media and Mab yield (R 2 = 0.652; P < 0.05). 2 . Analysis of glucose. The concentration of glucose was measured enzymatically at regular intervals from samples (1 ml) taken from the cultures described in Fig. 1. 
Effect of glucose concentration on LLO distribution
We investigated the effect of glucose concentration on the intracellular LLO composition in the CHO-EG2 cells. A metabolic sequence of lipid-linked oligosaccharide (LLO) structures leads to the tetradecasaccharide LLO (Glc 3 Man 9 GlcNAc 2 -P-P-dolichol) synthesized through a series of glycosyltransferase reactions prior to addition to N-glycan sequons in proteins in the endoplasmic reticulum (Karaoglu et al., 2001) . Three biological replicates of lipid extracts from the cell pellets of each of the 24 h cultures were analyzed by HILIC and structures were assigned from GU values found in the data base (GlycoBase). Peaks corresponding to the LLOs from each of the previously described cultures with varying glucose concentration cultures were compared (Fig. 3) . Samples from cultures containing 25 mM glucose displayed a prominent large peak with a GU value of 11.7 representing 63% of the total LLO and assigned as Table 1 Culture measurements following 24 h incubation at various glucose concentrations (n = 6). The initial cell density was 2.6 × 10 6 cells/ml in 80 ml.
Initial glucose (mM) the Glc 3 Man 9 GlcNAc 2 (Man9) structure (Fig. 3) . Prominent smaller peaks were identified as Glc 2 Man 9 GlcNAc 2 , Glc 1 Man 9 GlcNAc 2 , Man 9 GlcNAc 2 , Man 5 GlcNAc 2 (Man5) and Man 2 GlcNAc 2 (Man2) structures as labeled in Fig. 3 . The other minor peaks were unidentified. Those below a GU value of 4 were contaminants, also present in the blank. All the structures identified by HPLC were confirmed by MALDI-MS analysis (Fig. 4) . The LLOs were observed in the mass range 1239-2537 and all were detected without a free carbonyl reducing-terminus. The most abundant peak was observed at m/z 2373.8 and produced a fragmentation pattern corresponding to a glycan with a composition Hex 12 GlcNAc 2 . The identified structures represent steady state levels within the cell at the 24 h time point. For cells grown at an initial glucose concentration of less than 15 mM the predominant peak was Man2 with a significant level of the Man5 structure but the percentage of the Man9 structure was reduced significantly to 2.9% of the overall LLOs. It is important to note that these cultures (≤15 mM glucose) were under conditions of glucose depletion for at least 4 h prior to harvest.
Macroheterogeneity of purified antibodies
The effect of glucose concentration on glycan site occupancy (macroheterogeneity) was analyzed in Protein A purified antibodies from cultures after 24 h. Analysis on reduced SDS-PAGE gels showed visible antibody bands of approximately 40 kDa stained with CBB representing single heavy chains (HC; Fig. 5 ). The antibodies produced by cells grown in 17.5-25 mM glucose (Lane 6 and 7) displayed one single strong band corresponding to the glycosylated HC. Proteins isolated from cell culture with 15 mM initial glucose concentration (Lane 5) showed a faint band underneath the predominant gel band. The proportional density of the lower band in the 12.5 mM glucose sample was 26% which increased gradually to 52% for samples taken from cultures with no added glucose ( Table 1 ). The lower protein bands were suspected to be deglycosylated proteins due to an estimated 2% weight loss, which corresponds to the typical mass of glycan found on IgGs (Deisen-Q3 hofer, 1981). The identity of the lower band from the reduced gels was confirmed to be non-glycosylated HC by two methods. Firstly, the antibody purified from control culture (25 mM glucose) was subjected to partial digestion with PNGase F for 20 min. This resulted in a product which showed two gel bands at the same positions found for the samples from low glucose cultures. Secondly, samples of antibody showing two gel bands were analyzed by MALDI-MS (Fig. 6 ). This showed m/z values of 82,670 and 79,350 which are the expected masses of the glycosylated and non-glycosylated forms, respectively of the complete antibodies.
N-glycan microheterogeneity of EG2 antibodies
To compare the difference in glycosylation profiles of EG2 antibodies induced by various glucose concentrations, the glycans were released from the Protein A-purified Mabs with PNGase F, and analyzed by HILIC HPLC. The glycan pool was separated into six major peaks which eluted between 33 and 43 min with corresponding GU values between 5 and 9 (Fig. 7) . Structures were provisionally assigned from GU values with reference to the Glycobase and confirmed by a series of exoglycosidase enzyme array digestions. This allowed the identification of biantennary glycan structures with variable galactosylation (G), fucosylation (F) and sialylation (S), abbreviated as: G0F, G1F, G2F, G2FS1 and G2FS2. The predominant glycan structure of antibodies isolated from the 25 mM glucose culture was the fully galactosylated biantennary and fucosylated structure, G2F, which comprised 60% of the overall glycans. G0F and G1F structures were determined at 6% and 34%, respectively. The structures were found in samples Antibodies were isolated from the supernatants of the cultures after 24 h using a Protein A column. Glycans were released enzymically, 2-AB labeled, and detected via HILIC. Structural assignments of peaks were made as follows: (1) F(6)A2G0, (2) F(6)A2G1(1,6), (3) F(6)A2G1(1,3)), (4) (F(6)A2G2), (5) F(6)A2G2S1 and (6) F(6)A2G2S2.
from all cultures analyzed but there was a significant shift to lower galactosylation and sialylation in samples derived from cultures with lower glucose. Each glycan pool was assigned a galactosylation index (GI) and a sialylation index (SI) based upon the relative peak areas on the HPLC profile. In this experiment the GI value changed from 0.35 to 0.72 as the availability of glucose increased for the cells. Sialylation is dependent upon prior galactosylation of a glycan and consequently shows lower values with corresponding SI values from 0.019 to 0.058. There was a strong positive correlation between the GI and SI value determined for each sample and the time spent by the corresponding cells in glucose deprived media over the 24 h experimental period (R 2 = 0.965 and 0.936 for the GI and SI values respectively; Fig. 8 ).
Feeding regime to increase galactosylation
The high GI value determined for the EG2 antibody prompted a comparative study of another available human IgG1 (DP12) which we produced from CHO cells using the same culture conditions including the same growth medium. The glycan profile of the DP12 analyzed by HILIC showed similar structures as the EG2 with the presence of G0F, G1F, G2F, G2FS1 and G2FS2. These profiles in Fig. 9 were of higher sensitivity compared to Fig. 7 and also showed minor peaks identified as non-fucosylated structures. In a deliberate attempt to increase the galactosylation of these antibodies we exposed the cells to a culture feeding regime of uridine, manganese and galactose (UMG) as media supplements that previously had shown an enhancement of galactosylation (Gramer et al., 2011) . The results in Fig. 9 show that the UMG feeding regime produced a significant increase in the GI of both antibodies. However, the glycosylation pattern of the EG2 antibody showed significantly higher galactosylation compared to DP12 (Fig. 9a) . The GI of the EG2 increased from 0.73 to a high value of 0.83 whereas the DP12 increased from 0.30 to 0.43 (Fig. 9b) . These results suggest that the EG2 Mab is significantly more amenable to enzymic galactosylation compared to DP12.
Discussion
The rationale for studying the variability of antibody glycosylation with respect to nutrient concentrations in the medium is to develop an understanding of the effects of substrate depletion that may occur in mammalian cell cultures, particularly during fed-batch cultures that are designed to maintain low glucose and glutamine levels to prevent the accumulation of metabolic byproducts.
The functional importance of the consensus glycan structure on immunoglobulins has been widely recognized. Lower antibody galactosylation has been reported under inflammatory conditions such as rheumatoid arthritis. This is likely to be connected to an anti-inflammatory activity of fully galactosylated immunoglobulin which forms an immune complex with the inhibitory receptor Fc␥RIIB and promotes its association with dectin-1 (Karsten et al., 2012) . Reduced terminal galactosylation has also been shown to decrease complement-dependent cytotoxicity (CDC) in a human antibody (Hodoniczky et the proportion of sialylated antibody glycans is normally low (∼5% in vivo), sialylation has been proposed as a natural physiological switch to regulate the immune response upon antigenic challenge (Kaneko et al., 2006) . Antibodies with afucosylated glycans have been shown to have a ×100 increase in antibody-dependent cytotoxicity (ADCC) through enhanced affinity for the receptor Fc␥RIII present on NK cells and macrophages (Ferrara et al., 2011) . Because of these defined relationships between structure and function of the antibody glycans it is important at one level to control the consistency of glycosylation in a bioprocess and at a secondary level to promote the preferred glycosylation profile to ensure the targeted function.
In the experiments described in this paper we investigated the effect of lowered concentrations of glucose on the macroheterogeneity and microheterogeneity of glycans attached to a human-camelid antibody produced from CHO cells. The cells were inoculated at high density in media containing glucose from 0 to 25 mM. Not surprisingly the glucose was depleted at different time points over the course of the next 24 h in cultures containing <15 mM glucose. The time in which cells were exposed to media depleted of glucose varied between 4 and 24 h. Organic solvent extraction of the hydrophobic metabolites of the corresponding cell lysates enabled analysis of the lipid-linked oligosaccharides (LLOs) by HPLC separation and mass spectrometry. This identified a predominant 14-unit oligomer peak Glc 3 Man 9 GlcNac 2 under standard conditions of 25 mM glucose and is consistent with a previous report using a similar method (Jones et al., 2010) . This profile of LLOs represents the metabolic steady state at the time of harvest from these cultures. The fact that the metabolic precursors of this pathway were identified only as minor peaks of the HPLC separation probably indicates that the enzymic synthesis of the 14-unit glycan oligomer (Glc 3 Man 9 GlcNAc 2 -P-P-Dol) occurs rapidly compared to the next step which involves transfer of this consensus sequence to a growing peptide chain. The content of the 14-unit oligomer precursor was minimal in all samples taken from cultures in which there was evidence of glucose depletion. For example, even with a starting glucose concentration of 15 mM there was a 4 h period of glucose depletion prior to sampling which led to the absence of this precursor.
At low starting concentrations of glucose (<15 mM) the predominant LLO in our experiments was identified as Man 2 GlcNac 2 , an intermediate of this pathway. The accumulation of this intermediate suggests that the subsequent steps of the pathway were limited by the lack of availability of a monosaccharide substrate at the time of cell harvest. This is a comparable situation to the accumulation of specific LLO intermediates in cells subjected to enzymic mutations in the pathway (Jones et al., 2010) . In an earlier study it was shown that CHO cultures devoid of glucose synthesized Man 5 GlcNac 2 which was transferred to the nascent protein (Rearick et al., 1981) . In this case a minimal amount of mannose was available to the cells, which may account for the synthesis of a later intermediate than found in our experiments. Oligosaccharyltransferase (OST) is a key enzyme in glycosylation and responsible for the transfer of an LLO from dolichol on to the growing peptide chain (Mohorko et al., 2011) . This enzyme is highly specific and it has been shown that the absence of a single hexose residue from the 14-unit oligomer precursor LLO causes impaired recognition leading to reduced glycan occupancy on the synthesized protein.
Thus the presence of the smaller LLO oligomers observed in cells exposed to media with depleted glucose would be expected to lead to reduced glycan occupancy in a synthesized protein (Hulsmeier et al., 2007) .
We showed that the depletion of glucose resulted in decreased glycan occupancy by the appearance of a non-glycosylated antibody band following gel electrophoresis with no evidence of transfer of the Man 2 GlcNac 2 to the antibody. There was a strong positive correlation between the time period that the cells were exposed to glucose depletion over the 24-h incubation and the proportion of non-glycosylated antibody (R 2 = 0.95). The effect of glucose limitation on glycan occupancy has been shown previously for interferon-␥ production from CHO cells in chemostat cultures (Hayter et al., 1992) . It has also been shown that at low glucose concentrations there is preferential use of the substrate for energy metabolism rather than replenishing nucleotide-sugar pools that are the precursors of glycosylation (Nyberg et al., 1999) . Other studies have shown that a low metabolic energy status of cells can also contribute to low glycan occupancy (Kochanowski et al., 2008) .
Glycan microheterogeneity was manifested in our experiments by changes in the galactosylation and sialylation of the biantennary complex glycan structures identified from the purified antibodies obtained following cells incubated at various glucose concentrations. The predominant glycans on the antibody were G2F, G1F and G0F. Each sample was assigned an index (0-1) of galactosylation and sialylation based upon the glycosylation profile determined by HPLC. As the glucose concentration in the medium was decreased there was a shift to lower galactosylation and sialylation. Our results show a linear correlation between the cell specific glucose consumption over 24 h and the measured galactosylation and sialylation index of the purified antibody. This suggests that the observed decrease of galactosylation and sialylation was associated directly with the availability of the precursor.
Under standard conditions the galactosylation of the EG2 antibody appears to be significantly higher than many other antibodies reported in the literature (Table 2 ). Supplements such as uridine, manganese and galactose (UMG) that directly affect galactosylation have been shown to increase the GI (Gramer et al., 2011) and can be controlled to a desirable level using appropriate relative concentrations of the supplements (Grainger and James, 2013) . In our experiments we were able to enhance the GI of the EG2 antibody to a value of 0.83 using the UMG cocktail. Table 2 shows a list of GI values that have been calculated from previous reports of Mabs. These generally show lower GI values. Antibodies from pooled human serum showed a galactosylation index of 0.36 (Marino et al., 2010) . A review of commercially available Mabs shows that the galactosylation of murine cell derived Mabs is higher than those of CHO-derived Mabs (Raju and Jordan, 2012) . However, it is not clear that this is an intrinsic difference between cell lines because there are several reports of noncommercialized Mabs from CHO cells with higher GI values around 0.45 (Costa et al., 2013) . For Mabs derived from cells in culture it is clear that the extent of galactosylation varies with the culture conditions of the producer cell and environmental factors that may change significantly during the course of a batch culture as nutrients are utilized (Gramer et al., 2011) .
The control of culture parameters has shown that the GI value can be altered but only within certain limits. For example, it was shown that changes in the dissolved oxygen level from 10 to 100% altered the GI of a murine IgG between 0.41 and 0.56 (Kunkel et al., 1998) . For the two murine antibodies shown in Table 2 there appears to be a maximum GI value of 0.62 whereas the human or humanized antibodies appear to have significantly lower values of only up to 0.40. There are two reported exceptions of high values of 0.70 (Rose et al., 2013) and 0.83 (Jassal et al., 2001) , both of which are reported for antibodies with mutations in the Fc fragments.
The high level of galactosylation observed in the EG2 antibody was unexpected and may be related to structural differences between this camelid-human chimeric and other humanized antibodies such as the DP12 used in our experiments. The position of the conserved glycan in the restricted interstitial space between the Fc domains of the heavy chains of an antibody normally limits the accessibility of glycosyltransferase enzymes, notably galactosyltransferase and sialyltransferase (Jefferis, 2009) . It is possible that the smaller molecular weight structure of the EG2 antibody, which has no light chains enables a more relaxed and open structural environment around the glycan site. Furthermore, there are three amino acid mutations that were introduced during the construction of the Fc region that could account for a more open structure of this antibody. The two mutations most likely to affect the structure around the glycan site are D270G and Y278H both of which alter the size and charge of the associated amino acid residue. These mutations might enhance the accessibility of the glycosyltransferase enzymes,
